Novo Nordisk executive says expects FDA to enforce ban on copies of obesity drugs

LONDON/COPENHAGEN, May 7 (Reuters) - Novo Nordisk's head of U.S. operations said on Wednesday the company fully expects the U.S. Food and Drug Administration to enforce a ban on compounded copies of Wegovy and Ozempic when it comes into force on May 22.

"At that time, we will continue to fight against unlawful compounding," said David Moore, the company's executive vice president of U.S. operations, on an analyst call following the release of first-quarter results.